Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.

Br J Cancer · 2011 · PMC3251880 · PMID 22033270

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

In terms of the overall patient cell-death biomarker responses, there was a significant trend between increased dose of dulanermin and occurrence of any increase in circulating caspase 3/7 and gDNA levels 5 h after treatment ( Table 1 ).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.